AARTIDRUGS Aarti Drugs Q2 FY25 results (Jul–Sep 2024) and concall
Aarti Drugs reported a challenging Q2 FY25 with a 6% YoY revenue decline and reduced profitability, primarily due to lower realizations and subdued demand in the API segment. While API volumes showed QoQ growth, pricing pressures persisted. The company is optimistic about H2 FY25 and FY26, driven by the ramp-up of new capacities like Specialty Chemicals at Sayakha and Salicylic Acid, despite a downward revision of long-term revenue targets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 598 |
| EBITDA | 67 |
| Net profit | 35 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
